Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

555
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
555
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

679
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
679
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

648
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
648

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External validation of the DSP-risk score for prediction of clinically significant ventricular arrhythmias in primary prevention patients with desmoplakin cardiomyopathy-associated genetic variants.

Heart rhythm·2026
Same author

RBM20 Truncating Variants and Human Cardiomyopathy.

JAMA cardiology·2026
Same author

Laminopathies: natural history and risk prediction of heart failure.

European heart journal·2026
Same author

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.

Journal of the American College of Cardiology·2026
Same author

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.

Journal of the American College of Cardiology·2025
Same author

Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.

ESC heart failure·2025

Related Experiment Video

Updated: Feb 25, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Hypertrophic Cardiomyopathy.

Christopher Critoph1, Perry Elliott

  • 1The Heart Hospital, 16-18 Westmoreland Street, London, W1G 8PH, UK.

Cardiac Electrophysiology Clinics
|August 4, 2017
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy involves heart muscle thickening and can cause outflow tract obstruction. Management focuses on symptom relief and preventing sudden cardiac death through various interventions and risk stratification.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Related Experiment Videos

Last Updated: Feb 25, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a myocardial disease defined by hypertrophy, myocyte disarray, and fibrosis.
  • Genetic mutations in cardiac sarcomeric proteins are the primary cause of most HCM cases.
  • Patients experience diverse symptoms like chest pain, dyspnea, palpitations, and syncope across all age groups.

Purpose of the Study:

  • To summarize the key characteristics of hypertrophic cardiomyopathy.
  • To outline the primary complications, including sudden cardiac death, heart failure, and thromboembolism.
  • To review current management strategies for symptom alleviation and prevention of sudden death.

Main Methods:

  • Review of existing literature on hypertrophic cardiomyopathy.
  • Analysis of clinical presentation and diagnostic criteria.
  • Evaluation of therapeutic interventions for obstructive and non-obstructive HCM.

Main Results:

  • Twenty-five percent of patients develop a dynamic left ventricular outflow tract gradient.
  • Interventions targeting outflow tract obstruction often improve symptoms.
  • Risk stratification aids in preventing sudden death with implantable cardioverter defibrillators.

Conclusions:

  • Effective management of hypertrophic cardiomyopathy requires addressing symptoms and preventing sudden cardiac death.
  • Treatment strategies vary based on the presence and severity of left ventricular outflow tract obstruction.
  • Clinical risk stratification is crucial for guiding prophylactic therapy in high-risk individuals.